192 related articles for article (PubMed ID: 27754854)
21. Functional p53 determines docetaxel sensitivity in prostate cancer cells.
Liu C; Zhu Y; Lou W; Nadiminty N; Chen X; Zhou Q; Shi XB; deVere White RW; Gao AC
Prostate; 2013 Mar; 73(4):418-27. PubMed ID: 22996738
[TBL] [Abstract][Full Text] [Related]
22. Resistance to docetaxel-induced apoptosis in prostate cancer cells by p38/p53/p21 signaling.
Gan L; Wang J; Xu H; Yang X
Prostate; 2011 Aug; 71(11):1158-66. PubMed ID: 21656826
[TBL] [Abstract][Full Text] [Related]
23. DNA-PKc inhibition overcomes taxane resistance by promoting taxane-induced DNA damage in prostate cancer cells.
Chao OS; Goodman OB
Prostate; 2021 Oct; 81(14):1032-1048. PubMed ID: 34297853
[TBL] [Abstract][Full Text] [Related]
24. Metformin Improves Mitochondrial Respiratory Activity through Activation of AMPK.
Wang Y; An H; Liu T; Qin C; Sesaki H; Guo S; Radovick S; Hussain M; Maheshwari A; Wondisford FE; O'Rourke B; He L
Cell Rep; 2019 Nov; 29(6):1511-1523.e5. PubMed ID: 31693892
[TBL] [Abstract][Full Text] [Related]
25. Effect of mitochondrial metabolism-interfering agents on cancer cell mitochondrial function and radio/chemosensitivity.
Mitrakas AG; Kalamida D; Koukourakis MI
Anticancer Drugs; 2014 Nov; 25(10):1182-91. PubMed ID: 25035963
[TBL] [Abstract][Full Text] [Related]
26. Docetaxel induces Bcl-2- and pro-apoptotic caspase-independent death of human prostate cancer DU145 cells.
Ogura T; Tanaka Y; Tamaki H; Harada M
Int J Oncol; 2016 Jun; 48(6):2330-8. PubMed ID: 27082738
[TBL] [Abstract][Full Text] [Related]
27. Acquired drug resistance interferes with the susceptibility of prostate cancer cells to metabolic stress.
Catapano J; Luty M; Wróbel T; Pudełek M; Piwowarczyk K; Kędracka-Krok S; Siedlar M; Madeja Z; Czyż J
Cell Mol Biol Lett; 2022 Nov; 27(1):100. PubMed ID: 36401206
[TBL] [Abstract][Full Text] [Related]
28. Metformin and cancer.
Vallianou NG; Evangelopoulos A; Kazazis C
Rev Diabet Stud; 2013; 10(4):228-35. PubMed ID: 24841876
[TBL] [Abstract][Full Text] [Related]
29. Adiponectin and metformin additively attenuate IL1β-induced malignant potential of colon cancer.
Moon HS; Mantzoros CS
Endocr Relat Cancer; 2013 Dec; 20(6):849-59. PubMed ID: 24157941
[TBL] [Abstract][Full Text] [Related]
30. Convergence of IPMK and LKB1-AMPK signaling pathways on metformin action.
Bang S; Chen Y; Ahima RS; Kim SF
Mol Endocrinol; 2014 Jul; 28(7):1186-93. PubMed ID: 24877601
[TBL] [Abstract][Full Text] [Related]
31. Everolimus (RAD001) sensitizes prostate cancer cells to docetaxel by down-regulation of HIF-1α and sphingosine kinase 1.
Alshaker H; Wang Q; Kawano Y; Arafat T; Böhler T; Winkler M; Cooper C; Pchejetski D
Oncotarget; 2016 Dec; 7(49):80943-80956. PubMed ID: 27821815
[TBL] [Abstract][Full Text] [Related]
32. Concurrent regulation of LKB1 and CaMKK2 in the activation of AMPK in castrate-resistant prostate cancer by a well-defined polyherbal mixture with anticancer properties.
MacDonald AF; Bettaieb A; Donohoe DR; Alani DS; Han A; Zhao Y; Whelan J
BMC Complement Altern Med; 2018 Jun; 18(1):188. PubMed ID: 29914450
[TBL] [Abstract][Full Text] [Related]
33. A novel histone deacetylase inhibitor, CG200745, potentiates anticancer effect of docetaxel in prostate cancer via decreasing Mcl-1 and Bcl-XL.
Hwang JJ; Kim YS; Kim T; Kim MJ; Jeong IG; Lee JH; Choi J; Jang S; Ro S; Kim CS
Invest New Drugs; 2012 Aug; 30(4):1434-42. PubMed ID: 21773733
[TBL] [Abstract][Full Text] [Related]
34. miR-375 induces docetaxel resistance in prostate cancer by targeting SEC23A and YAP1.
Wang Y; Lieberman R; Pan J; Zhang Q; Du M; Zhang P; Nevalainen M; Kohli M; Shenoy NK; Meng H; You M; Wang L
Mol Cancer; 2016 Nov; 15(1):70. PubMed ID: 27832783
[TBL] [Abstract][Full Text] [Related]
35. Phosphorylation of serine 399 in LKB1 protein short form by protein kinase Cζ is required for its nucleocytoplasmic transport and consequent AMP-activated protein kinase (AMPK) activation.
Zhu H; Moriasi CM; Zhang M; Zhao Y; Zou MH
J Biol Chem; 2013 Jun; 288(23):16495-16505. PubMed ID: 23612973
[TBL] [Abstract][Full Text] [Related]
36. HIV-1 protease inhibitor, ritonavir: a potent inhibitor of CYP3A4, enhanced the anticancer effects of docetaxel in androgen-independent prostate cancer cells in vitro and in vivo.
Ikezoe T; Hisatake Y; Takeuchi T; Ohtsuki Y; Yang Y; Said JW; Taguchi H; Koeffler HP
Cancer Res; 2004 Oct; 64(20):7426-31. PubMed ID: 15492266
[TBL] [Abstract][Full Text] [Related]
37. Metformin amplifies chemotherapy-induced AMPK activation and antitumoral growth.
Rocha GZ; Dias MM; Ropelle ER; Osório-Costa F; Rossato FA; Vercesi AE; Saad MJ; Carvalheira JB
Clin Cancer Res; 2011 Jun; 17(12):3993-4005. PubMed ID: 21543517
[TBL] [Abstract][Full Text] [Related]
38. Targeting CDC25C, PLK1 and CHEK1 to overcome Docetaxel resistance induced by loss of LZTS1 in prostate cancer.
Al Nakouzi N; Cotteret S; Commo F; Gaudin C; Rajpar S; Dessen P; Vielh P; Fizazi K; Chauchereau A
Oncotarget; 2014 Feb; 5(3):667-78. PubMed ID: 24525428
[TBL] [Abstract][Full Text] [Related]
39. The protective role of AMP-activated protein kinase in alpha-synuclein neurotoxicity in vitro.
Dulovic M; Jovanovic M; Xilouri M; Stefanis L; Harhaji-Trajkovic L; Kravic-Stevovic T; Paunovic V; Ardah MT; El-Agnaf OM; Kostic V; Markovic I; Trajkovic V
Neurobiol Dis; 2014 Mar; 63():1-11. PubMed ID: 24269733
[TBL] [Abstract][Full Text] [Related]
40. Metformin and AICAR regulate NANOG expression via the JNK pathway in HepG2 cells independently of AMPK.
Shen C; Ka SO; Kim SJ; Kim JH; Park BH; Park JH
Tumour Biol; 2016 Aug; 37(8):11199-208. PubMed ID: 26939902
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
